Dimensional Fund Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$581M Buy
1,168,956
+179,614
+18% +$79.6M 0.11% 149
2026
Q1
$442M Buy
989,342
+43,682
+5% +$20.4M 0.09% 196
2025
Q4
$429M Buy
945,660
+162,074
+21% +$69.9M 0.09% 192
2025
Q3
$307M Buy
783,586
+187,359
+31% +$78.3M 0.07% 314
2025
Q2
$265M Sell
596,227
-9,652
-2% -$4.45M 0.06% 355
2025
Q1
$294M Sell
605,879
-21,638
-3% -$10.1M 0.07% 274
2024
Q4
$253M Sell
627,517
-20,291
-3% -$9.41M 0.06% 359
2024
Q3
$301M Sell
647,808
-15,149
-2% -$7.28M 0.07% 285
2024
Q2
$311M Buy
662,957
+75,045
+13% +$32.6M 0.08% 223
2024
Q1
$246M Buy
587,912
+2,696
+0.5% +$1.14M 0.07% 325
2023
Q4
$238M Sell
585,216
-7,179
-1% -$2.65M 0.07% 306
2023
Q3
$206M Sell
592,395
-18,304
-3% -$6.4M 0.07% 312
2023
Q2
$215M Sell
610,699
-10,116
-2% -$3.41M 0.07% 306
2023
Q1
$196M Sell
620,815
-159,687
-20% -$47.9M 0.07% 326
2022
Q4
$225K Sell
780,502
-83,805
-10% -$25.5M 0.07% 273
2022
Q3
$250M Sell
864,307
-17,338
-2% -$4.99M 0.1% 200
2022
Q2
$248M Sell
881,645
-71,529
-8% -$19.1M 0.09% 213
2022
Q1
$249M Buy
953,174
+19,141
+2% +$4.54M 0.08% 279
2021
Q4
$205M Buy
934,033
+229,487
+33% +$44.6M 0.06% 361
2021
Q3
$128M Buy
704,546
+185,523
+36% +$36.2M 0.04% 635
2021
Q2
$105M Buy
519,023
+49,412
+11% +$10.3M 0.03% 814
2021
Q1
$101M Buy
469,611
+15,062
+3% +$3.31M 0.03% 823
2020
Q4
$107M Buy
454,549
+18,974
+4% +$4.35M 0.04% 685
2020
Q3
$119M Buy
435,575
+3,625
+0.8% +$1M 0.05% 456
2020
Q2
$125M Buy
431,950
+35,100
+9% +$9.52M 0.06% 400
2020
Q1
$94.4M Buy
396,850
+22,425
+6% +$5.14M 0.05% 462
2019
Q4
$82M Buy
374,425
+1,852
+0.5% +$375K 0.03% 904
2019
Q3
$63.1M Buy
372,573
+1,056
+0.3% +$187K 0.02% 1150
2019
Q2
$68.1M Buy
371,517
+6,005
+2% +$1.05M 0.03% 1081
2019
Q1
$67.2M Buy
365,512
+40,427
+12% +$7.47M 0.03% 1066
2018
Q4
$53.9M Buy
325,085
+11,848
+4% +$2.05M 0.02% 1151
2018
Q3
$60.4M Sell
313,237
-8,109
-3% -$1.44M 0.02% 1242
2018
Q2
$54.6M Buy
321,346
+200
+0.1% +$31K 0.02% 1321
2018
Q1
$52.3M Buy
321,146
+8,640
+3% +$1.41M 0.02% 1292
2017
Q4
$46.8M Buy
312,506
+15,625
+5% +$2.31M 0.02% 1420
2017
Q3
$45.1M Buy
296,881
+14,066
+5% +$2.12M 0.02% 1405
2017
Q2
$36.4M Buy
282,815
+9,882
+4% +$1.19M 0.02% 1572
2017
Q1
$29.8M Buy
272,933
+5,496
+2% +$484K 0.01% 1704
2016
Q4
$19.7M Buy
267,437
+8,524
+3% +$694K 0.01% 1990
2016
Q3
$22.6M Buy
258,913
+9,896
+4% +$935K 0.01% 1823
2016
Q2
$21.4M Buy
249,017
+810
+0.3% +$70K 0.01% 1776
2016
Q1
$19.7M Buy
248,207
+8,583
+4% +$776K 0.01% 1823
2015
Q4
$30.2M Buy
239,624
+14,019
+6% +$1.69M 0.02% 1388
2015
Q3
$23.5M Sell
225,605
-113
-0.1% -$14.5K 0.02% 1577
2015
Q2
$27.9M Sell
225,718
-5,656
-2% -$713K 0.02% 1503
2015
Q1
$27.3M Buy
231,374
+1,117
+0.5% +$134K 0.02% 1474
2014
Q4
$27.4M Buy
230,257
+2,319
+1% +$261K 0.02% 1405
2014
Q3
$25.6M Buy
227,938
+2,163
+1% +$206K 0.02% 1356
2014
Q2
$21.4M Sell
225,775
-523
-0.2% -$36.7K 0.01% 1596
2014
Q1
$16M Buy
226,298
+2,655
+1% +$210K 0.01% 1795
2013
Q4
$16.6M Buy
223,643
+16,274
+8% +$1.13M 0.01% 1724
2013
Q3
$15.7M Buy
207,369
+60,681
+41% +$4.83M 0.01% 1696
2013
Q2
$11.7M Buy
+146,688
New +$10.8M 0.01% 1869

Other funds holding VRTX

Dimensional Fund Advisors's VRTX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 18% in Q2 2026, buying an estimated $79.6M and bringing the position to 1,168,956 shares worth $581M. The position accounts for 0.11% of the portfolio, ranked #149.

Dimensional Fund Advisors first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Dimensional Fund Advisors held 1,168,956 shares of Vertex Pharmaceuticals worth $581M as of Q2 2026.
  • Dimensional Fund Advisors bought 179,614 Vertex Pharmaceuticals shares in Q2 2026, an estimated $79.6M.
  • Vertex Pharmaceuticals made up 0.11% of Dimensional Fund Advisors's portfolio in Q2 2026, its #149 holding.
  • Dimensional Fund Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.